Metabolism of bradykinin in vivo in humans: Identification of BK1-5 as a stable plasma peptide metabolite

Journal of Pharmacology and Experimental Therapeutics

Volumn 294, Issue 1, 2000, Pages 263-269

  Murphey, Laine J ^a,b   Hachey, David L ^b   Oates, John A ^a,b   Morrow, Jason D ^a,b   Brown, Nancy J ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ RECEPTOR; BRADYKININ[1-5]; DRUG METABOLITE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TASTE DISORDER;

ADULT; BRADYKININ; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; PEPTIDE FRAGMENTS;

EID: 0033946043     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Abe K, Sato M, Kasai Y, Haruyama T, Sato K, Miyazaki S, Imai Y, Hiwatari M, Itoh T, Sakurai Y, Goto T, Tajima J, Seino M and Yoshinaga K (1981) A circadian variation in the excretion of urinary kinin, kallikrein and prostaglandin E in normal volunteers. Jpn Circ J 45:1098-1103.
2. Bhoola KD, Figueroa CD and Worthy K (1992) Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev 44:1-80.
3. Bonner G, Iwersen D and Shimamoto K (1987) The analytical value for kinin concentration in blood depends on the antiserum used in the bradykinin radioimmunoassay. J Clin Chem Clin Biochem 25:39-43.
4. Bonner G, Preis S, Schunk U, Wagmann M, Chrosch R and Toussaint C (1992) Effect of bradykinin on arteries and veins in systemic and pulmonary circulation. J Cardiovasc Pharmacol 20:S21-S27.
5. Brash AH, Jackson EK, Saggese CA, Lawson JA, Oates JA and FitzGerald GA (1983) Metabolic disposition of prostacyclin in humans. J Pharmacol Exp Ther 226:78-87.
6. Brown NJ, Gainer JV, Stein CM and Vaughan DE (1999) Bradykinin stimulates t-PA release in human vasculature. Hypertension 33:1431-1435.
7. Brown NJ, Ryder D, Gainer JV, Morrow JD and Nadeau J (1996) Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. J Pharmacol Exp Ther 279:703-712.
8. Carone FA, Pullman TN, Oparil S and Nakamura S (1976) Micropuncture evidence of rapid hydrolysis of bradykinin by rat proximal tubule. Am J Physiol 230:1420-1424.
9. 9]BK: Influence of enalaprilat. Am J Physiol 96:H1340-H1347.
10. Dikler S, Kelly JW and Russell DH (1997) Improving mass spectrometric sequencing of arginine-containing peptides by derivatization with acetylacetone. J Mass Spectrom 32:1337-1349.
11. Emeis JJ and Tranquille N (1992) On the role of bradykinin in secretion from vascular endothelial cells. Agents Actions 38:285-291.
12. 2. Anal Biochem 115:359-367.
13. Ferreira SH and Vane JR (1967) The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Br J Pharmacol Chemother 30:417-424.
14. Gainer JV, Morrow JD, Loveland A, King DJ and Brown NJ (1998) Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339:1285-1292.
15. Goodfriend TL and Odya CE (1979) Bradykinin, in Methods of Hormone Radioimmunoassay (Jaffe BM and Behrman HR eds) pp 909-923, Academic Press, New York.
16. Hasan AAK, Amenta S and Schmaier AH (1996) Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of α-thrombin-induced platelet activation. Circulation 94:517-528.
17. Hasan AAK, Rebello SS, Smith E, Srikanth S, Werns S, Driscoll E, Faul J, Brenner D, Normolle D, Lucchesi BR and Schmaier AH (1999) Thrombostatin inhibits induced canine coronary thrombosis. Thromb Haemostasis 82:1182-1187.
18. Hial V, Keiser HR and Pisano JJ (1976) Origin and content of methionyl-lysyl-bradykinin, lysyl-bradykinin and bradykinin in human urine. Biochem Pharmacol 25:2499-2503.
19. Hilgenfeldt U, Linke R, Riester U, Konig W and Breipohl G (1995) Strategy of measuring bradykinin and kallidin and their concentration in plasma and urine. Anal Biochem 228:35-41.
20. Hilgenfeldt U, Puschner T, Riester U, Finsterle J, Hilgenfeldt J and Ritz E (1998) Low-salt diet downregulates plasma but not tissue kallikrein-kinin system. Am J Physiol 275:F88-F93.
21. Kaplan AP, Joseph K, Shibayama Y, Reddigari S, Ghebrehiwet B and Silverberg M (1997) The intrinsic coagulation/kinin-forming cascade: Assembly in plasma and cell surfaces in inflammation. Adv Immunol 66:225-272.
22. Linz W, Wiemer G, Gohlke P, Unger T and Scholkens BA (1995) Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47:25-49.
23. Majima M, Nishiyama K, Iguchi Y, Yao K, Ogino M, Ohno T, Sunahara N, Katoh K, Tatemichi N, Takei Y and Katori M (1996) Determination of bradykinin-(1-5) in inflammatory exudate by a new ELISA as a reliable indicator of bradykinin generation. Inflamm Res 45:416-423.
24. Margolius HS (1995) Kallikreins and kinins: Some unanswered questions about system characteristics and roles in human disease. Hypertension 26:221-229.
25. Margolius HS, Geller R, Pisano JJ and Sjoerdsma A (1971) Altered urinary kallikrein excretion in human hypertension. Lancet 2:1063-1065.
26. Nasjletti A, Colina-Chourio J and McGiff JC (1975) Disappearance of bradykinin in the renal circulation of dogs. Effects of kininase inhibition. Circ Res 37:59-65.
27. Papayannopoulos IA (1995) The interpretation of collision-induced dissociation tandem mass spectra of peptides. Mass Spectrom Rev 14:49-73.
28. Parratt JR, Vegh A, Zeitlin IJ, Ahmad M, Oldroyd K, Kaszala K and Papp JG (1997) Bradykinin and endothelial-cardiac myocyte interactions in ischemic preconditioning. Am J Cardiol 80:124A-131A.
29. Pellacani A, Brunner HR and Nussberger J (1992) Antagonizing and measurement: Approaches to understanding of hemodynamic effects of kinins. J Cardiovasc Pharmacol 20:S28-S34.
30. Prechel MM, Orawski AT, Maggiora LL and Simmons WH (1995) Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung. J Pharmacol Exp Ther 275:1136-1142.
31. Ritchie RH, Schiebinger RJ, LaPointe MC and Marsh JD (1998) Angiotensin Il-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide Am J Physiol 275:H1370-H1374.
32. Ryan JW, Berryer P, Chung AY and Sheffy DH (1994) Characterization of rat pulmonary vascular aminopeptidase P in vivo: Role in the inactivation of bradykinin. J Pharmacol Exp Ther 269:941-947.
33. Saito M, Majima M, Katori M, Sanjou Y, Suyama I, Shiokawa H, Koshiba K and Aoyagi T (1995) Degradation of bradykinin in human urine by carboxypeptidase Y-like exopeptidase and neutral endopeptidase and their inhibition by ebelactone B and phosphoramidon. Int J Tissue React 17:181-190.
34. 9-bradykinin by angiotensin converting enzyme. Biockem Pharmacol 35:1951-1956.
35. Sheikh IA and Kaplan AP (1986b) Studies of the digestion of bradykinin, lysyl bradykinin, and kinin-degradation products by carboxypeptidases A, B, and N. Biochem Pharmacol 35:1957-1963.
36. Shima C, Majima M and Katori M (1992) A stable metabolite, Arg-Pro-Pro-Gly-Phe, of bradykinin in the degradation pathway in human plasma. Jpn J Pharmacol 60:111-119.
37. Simmons WH and Orawski AT (1992) Membrane-bound aminopepudase P from bovine lung. Its purification, properties, and degradation of bradykinin. J Biol Chem 267: 4897-4903.
38. Vanhoutte PM (1989) Endothelium and control of vascular function: State of the art lecture. Hypertension 13:658-667.